Author:
Ribrag Anne,Lissavalid Emilie,Fayard Juliette,Djerroudi Lounes,Ghislain Mathilde Saint,Ramtohul Toulsie,Tardivon Anne
Reference31 articles.
1. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis;Broglio;JAMA,2016
2. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials;Early Breast Cancer Trialists’ Collaborative group (EBCTCG);Lancet Oncol.,2021
3. Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis;Davey;BJS Open,2022
4. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis;Mao;PLoS One,2014
5. Predictors of neoadjuvant chemotherapy response in breast cancer: A review;Xu;OncoTargets,2020